Astellas Pharma Inc (ALPMY)
9.97
+0.27
(+2.78%)
USD |
OTCM |
May 02, 16:00
Astellas Pharma Cash from Operations (Quarterly): 340.83M for Dec. 31, 2023
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 340.83M |
| September 30, 2023 | 250.90M |
| June 30, 2023 | 88.89M |
| March 31, 2023 | 922.33M |
| December 31, 2022 | 492.58M |
| September 30, 2022 | 635.54M |
| June 30, 2022 | 376.86M |
| March 31, 2022 | 455.92M |
| December 31, 2021 | 570.94M |
| September 30, 2021 | 900.16M |
| June 30, 2021 | 366.19M |
| March 31, 2021 | 738.82M |
| December 31, 2020 | 1.072B |
| September 30, 2020 | 882.48M |
| June 30, 2020 | 200.73M |
| March 31, 2020 | 476.50M |
| December 31, 2019 | 618.28M |
| September 30, 2019 | 880.34M |
| June 30, 2019 | 67.44M |
| March 31, 2019 | 526.23M |
| December 31, 2018 | 801.05M |
| September 30, 2018 | 664.73M |
| June 30, 2018 | 340.88M |
| March 31, 2018 | 914.80M |
| December 31, 2017 | 867.55M |
| Date | Value |
|---|---|
| September 30, 2017 | 503.68M |
| June 30, 2017 | 535.45M |
| March 31, 2017 | 470.63M |
| December 31, 2016 | 828.05M |
| September 30, 2016 | 711.99M |
| June 30, 2016 | 168.05M |
| March 31, 2016 | 1.176B |
| December 31, 2015 | 660.36M |
| September 30, 2015 | 533.29M |
| June 30, 2015 | 244.36M |
| March 31, 2015 | 364.78M |
| December 31, 2014 | 390.53M |
| September 30, 2014 | 367.25M |
| June 30, 2014 | 593.74M |
| March 31, 2014 | 508.83M |
| December 31, 2013 | 703.14M |
| September 30, 2013 | 464.79M |
| June 30, 2013 | 462.43M |
| March 31, 2011 | 162.73M |
| December 31, 2010 | 521.08M |
| September 30, 2010 | 142.20M |
| June 30, 2010 | 342.81M |
| March 31, 2010 | 396.40M |
| December 31, 2009 | 259.52M |
| September 30, 2009 | 557.80M |
Cash From Operations Definition
Cash flow from operations is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall operating activities of the company. A few examples of operating activities include change in receivables, change in inventories, and changes in current assets.
Cash from Operations (Quarterly) Range, Past 5 Years
67.44M
Minimum
Jun 2019
1.072B
Maximum
Dec 2020
544.12M
Average
492.58M
Median
Dec 2022
Cash from Operations (Quarterly) Benchmarks
| Takeda Pharmaceutical Co Ltd | 948.05M |
| Nxera Pharma Co Ltd | -6.804M |
| PeptiDream Inc | 24.93M |
| Stemcell Holdings Inc | 0.8509M |
| Healios KK | -8.04M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | -155.23M |
| Cash from Financing (Quarterly) | -690.16M |
| Free Cash Flow | 952.05M |
| Free Cash Flow Per Share (Quarterly) | 0.1358 |
| Free Cash Flow to Equity (Quarterly) | 23.46M |
| Free Cash Flow to Firm (Quarterly) | 253.89M |
| Free Cash Flow Yield | 5.28% |